• awesomeicons6/solid/lock 100% Secure Online Payments

AMH CLIA

£0.00
Ansh Labs

AMH CLIA (AL-205-i (CE))

View Data Sheet
The UltraSensitive Anti-müllerian hormone/ müllerian inhibiting substance (US AMH/MIS) enzyme linked chemiluminescent immunuoassay (CLIA) kit provides materials for the quantitative measurement of AMH/MIS in human serum and other biological fluids.

Product

Cat #  AL-205-i (CE) Size  96 Well Plate Price 

Description

Anti-Müllerian hormone (AMH), a member of the TGFβ superfamily, is a homodimeric glycoprotein composed of two 55 kDa N-terminal and two 12.5 kDa C-terminal homodimers, non-covalently linked by disulfide bridges.1

Recent studies have shown that the AMH C-terminal homodimer is much less active than the noncovalent complex, but almost all activity can be restored by associating with the N-terminal pro-region, which reforms a complex with the mature C-terminal homodimer. This finding raises the possibility that the AMH noncovalent complex is the active form of protein. It was reported that the cleaved AMH noncovalent complex binds to AMHRII and stimulates intracellular signaling, whereas full-length AMH shows only minimal activity.2

AMH is secreted by the Sertoli cells in males. During embryonic development, AMH is responsible for Müllerian duct regression. AMH continues to be produced by the testes until puberty and then decreases slowly to residual post-puberty values. In females, AMH is produced by the granulosa cells of small growing follicles from the 36th week of gestation onwards until menopause when levels become undetectable. Potential clinical applications of low end anti-müllerian hormone (AMH) have been published in premature ovarian insufficiency, ovarian tumors, menopause and many more.

References:
1. Pepinski, R.B., et al. (1988) J. Biol. Chem., 263, 18961-18964.
2. di Clemente et al. Mol Endocrinol, November 2010, 24 (11): 2193-2206.
3. HHS Publication, 5th ed., 2007. Biosafety in Microbiological and Biomedical Laboratories. Available http://www.cdc.gov/biosafety/publications/bmbl5/BMBL5
4. DHHS (NIOSH) Publication No. 78€“127, August 1976. Current Intelligence Bulletin 13 - Explosive Azide Hazard. Available http:// www.cdc.gov/niosh.
5. Approved Guideline €“ Procedures for the Handling and Processing of Blood Specimens, H18-A3. 2004. Clinical and Laboratory Standards Institute.
6. Kricka L. Interferences in immunoassays €“ still a threat. Clin Chem 2000; 46: 1037€“1038.

Specifications

Product Size 96 Well Plate
Analyte AMH
Assay Time 2.5 hours
Detection HRP-based enhanced chemiluminescence, utilizing our proprietary AnshLite„¢ luminogenic substrate
Dynamic Range 6, 0.09-20.2 ng/mL
Detection Limit 29 pg/mL
Product Line Immunoassay
Special Notes For in vitro diagnostic use.
Sample Size 50 µL
Samples Plasma,Serum
Shelf Life 24 months
Reactivity Human, Non-Human Primate